

# Mariusz Tomaniak

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1575859/publications.pdf>

Version: 2024-02-01

79  
papers

1,219  
citations

516215

16  
h-index

454577

30  
g-index

79  
all docs

79  
docs citations

79  
times ranked

1666  
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnostic Accuracy of Coronary Angiography-Based Vessel Fractional Flow Reserve (vFFR) Virtual Stenting. <i>Journal of Clinical Medicine</i> , 2022, 11, 1397.	1.0	4
2	Intravascular Lithotripsy for the Treatment of Stent Underexpansion: The Multicenter IVL-DRAGON Registry. <i>Journal of Clinical Medicine</i> , 2022, 11, 1779.	1.0	16
3	Comparison of diagnostic accuracy measures of novel 3D quantitative coronary angiography based software and diastolic pressure ratio for fractional flow Reserve. A single center pooled analysis of FAST EXTEND and FAST II studies. <i>IJC Heart and Vasculature</i> , 2022, 39, 100986.	0.6	1
4	Three-dimensional QCA-based vessel fractional flow reserve (vFFR) in Heart Team decision-making: a multicentre, retrospective, cohort study. <i>BMJ Open</i> , 2022, 12, e054202.	0.8	2
5	Angiography-Based Fractional Flow Reserve: State of the Art. <i>Current Cardiology Reports</i> , 2022, 24, 667-678.	1.3	12
6	The prognostic value of angiography-based vessel fractional flow reserve after percutaneous coronary intervention: The FAST Outcome study. <i>International Journal of Cardiology</i> , 2022, 359, 14-19.	0.8	8
7	Circulating and Platelet MicroRNAs in Cardiovascular Risk Assessment and Antiplatelet Therapy Monitoring. <i>Journal of Clinical Medicine</i> , 2022, 11, 1763.	1.0	9
8	Near-infrared spectroscopy to predict plaque progression in plaque-free artery regions. <i>EuroIntervention</i> , 2022, 18, 253-261.	1.4	4
9	Comparative Appraisal of Intravascular Ultrasound and Optical Coherence Tomography in Invasive Coronary Imaging: 2022 Update. <i>Journal of Clinical Medicine</i> , 2022, 11, 4055.	1.0	8
10	Influence of Bleeding Risk on Outcomes of Radial and Femoral Access for Percutaneous Coronary Intervention: An Analysis From the GLOBAL LEADERS Trial. <i>Canadian Journal of Cardiology</i> , 2021, 37, 122-130.	0.8	4
11	Correlation between 3D-QCA based FFR and quantitative lumen assessment by IVUS for left main coronary artery stenoses. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, E495-E501.	0.7	11
12	The ultra-thin strut sirolimus-eluting coronary stent: SUPRAFLEX. <i>Future Cardiology</i> , 2021, 17, 227-237.	0.5	5
13	Safety and Efficacy of 1-Month Dual Antiplatelet Therapy (Ticagrelor + Aspirin) Followed by 23-Month Ticagrelor Monotherapy in Patients Undergoing Staged Percutaneous Coronary Intervention (A) <i>Tj ETQq1 1 0.784314 rgBT /@verlock</i>		
14	Inflammation as a determinant of healing response after coronary stent implantation. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 791-801.	0.7	12
15	Predicting 2-year all-cause mortality after contemporary <sc>PCI</sc>: Updating the logistic clinical <sc>SYNTAX</sc> score. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 1287-1297.	0.7	6
16	Impact of chronic obstructive pulmonary disease on 10-year mortality after percutaneous coronary intervention and bypass surgery for complex coronary artery disease: insights from the SYNTAX Extended Survival study. <i>Clinical Research in Cardiology</i> , 2021, 110, 1083-1095.	1.5	10
17	OCT-Derived Plaque Morphology and FFR-Determined Hemodynamic Relevance in Intermediate Coronary Stenoses. <i>Journal of Clinical Medicine</i> , 2021, 10, 2379.	1.0	8
18	Ticagrelor alone vs. dual antiplatelet therapy from 1 month after drug-eluting coronary stenting among patients with STEMI: a post hoc analysis of the randomized GLOBAL LEADERS trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 756-773.	0.4	1

#	ARTICLE	IF	CITATIONS
19	Serial Baseline, 12-, 24-, and 60-Month Optical Coherence Tomography Evaluation of ST Segment Elevation Myocardial Infarction Patients Treated with Absorb Bioresorbable Vascular Scaffold. <i>American Journal of Cardiology</i> , 2021, 155, 23-31.	0.7	1
20	Atherogenesis in Native Coronary Segments and In-Stent Neoatherogenesis Beyond Three Years After First-Generation Drug-Eluting Stent Implantation: Angiographic and Optical Coherence Tomography Study. <i>Journal of Invasive Cardiology</i> , 2021, 33, E738-E747.	0.4	0
21	Two years clinical outcomes with the state-of-the-art PCI for the treatment of bifurcation lesions: A sub-analysis of the SYNTAX II study. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 10-17.	0.7	1
22	Clinical relevance of ticagrelor monotherapy following 1-month dual antiplatelet therapy after bifurcation percutaneous coronary intervention: Insight from GLOBAL LEADERS trial. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 100-111.	0.7	16
23	Second generation, sirolimus-eluting, bioresorbable Tyrocore scaffold implantation in patients with ST-segment elevation myocardial infarction: Baseline OCT and 30-day clinical outcomes – A FANTOM STEMI pilot study. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, E1-E7.	0.7	9
24	Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention. <i>JAMA Cardiology</i> , 2020, 5, 21.	3.0	49
25	Association of Pulse Pressure With Clinical Outcomes in Patients Under Different Antiplatelet Strategies After Percutaneous Coronary Intervention: Analysis of GLOBAL LEADERS. <i>Canadian Journal of Cardiology</i> , 2020, 36, 747-755.	0.8	2
26	Impact of chronic obstructive pulmonary disease and dyspnoea on clinical outcomes in ticagrelor treated patients undergoing percutaneous coronary intervention in the randomized GLOBAL LEADERS trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 222-230.	1.4	7
27	Impact of established cardiovascular disease on outcomes in the randomized global leaders trial. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 1369-1378.	0.7	6
28	Impact of recruitment and retention on all-cause mortality in a large all-comers randomised controlled trial: insights from the GLOBAL LEADERS trial. <i>Clinical Research in Cardiology</i> , 2020, 109, 918-929.	1.5	3
29	Association between post-percutaneous coronary intervention bivalirudin infusion and net adverse clinical events: a post hoc analysis of the GLOBAL LEADERS study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 22-30.	1.4	7
30	Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial. <i>Cardiovascular Diabetology</i> , 2020, 19, 179.	2.7	14
31	Endothelial shear stress and vascular remodeling in bioresorbable scaffold and metallic stent. <i>Atherosclerosis</i> , 2020, 312, 79-89.	0.4	3
32	Efficacy and safety of one-month DAPT followed by 23-month ticagrelor monotherapy in patients undergoing proximal LAD stenting: Insights from the GLOBAL LEADERS trial. <i>International Journal of Cardiology</i> , 2020, 320, 27-34.	0.8	4
33	The Impact of Coronary Physiology on Contemporary Clinical Decision Making. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1617-1638.	1.1	60
34	Advances in IVUS/OCT and Future Clinical Perspective of Novel Hybrid Catheter System in Coronary Imaging. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 119.	1.1	65
35	Comparative Methodological Assessment of the Randomized GLOBAL LEADERS Trial Using Total Ischemic and Bleeding Events. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006660.	0.9	11
36	Impact of Bleeding and Myocardial Infarction on Mortality in All-Comer Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009177.	1.4	15

#	ARTICLE	IF	CITATIONS
37	Impact of white blood cell count on clinical outcomes in patients treated with aspirin-free ticagrelor monotherapy after percutaneous coronary intervention: insights from the GLOBAL LEADERS trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, , .	1.4	10
38	Vulnerable plaques and patients: state-of-the-art. <i>European Heart Journal</i> , 2020, 41, 2997-3004.	1.0	98
39	Drug-eluting bioresorbable scaffolds in cardiovascular disease, peripheral artery and gastrointestinal fields: a clinical update. <i>Expert Opinion on Drug Delivery</i> , 2020, 17, 931-945.	2.4	6
40	Comparative Assessment of Predictive Performance of PRECISE-DAPT, CRUSADE, and ACUITY Scores in Risk Stratifying 30-Day Bleeding Events. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1087-1095.	1.8	14
41	Predictors for Clinical Outcome of Untreated Stent Edge Dissections as Detected by Optical Coherence Tomography. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008685.	1.4	12
42	DAPT Score and the Impact of Ticagrelor Monotherapy During the Second Year After PCI. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 634-646.	1.1	17
43	Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: Pre-specified subgroup analysis from the randomized GLOBAL LEADERS study. <i>Atherosclerosis</i> , 2020, 295, 45-53.	0.4	36
44	Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial. <i>Clinical Research in Cardiology</i> , 2020, 109, 930-943.	1.5	14
45	The impact of pre-procedure heart rate on adverse clinical outcomes in patients undergoing percutaneous coronary intervention: Results from a 2-year follow-up of the GLOBAL LEADERS trial. <i>Atherosclerosis</i> , 2020, 303, 1-7.	0.4	1
46	Usefulness of the updated logistic clinical SYNTAX score after percutaneous coronary intervention in patients with prior coronary artery bypass graft surgery: Insights from the GLOBAL LEADERS trial. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, E516-E526.	0.7	5
47	Peri-strut low intensity areas and in-scaffold neointima growth after bioresorbable scaffold implantation in STEMI. A serial optical coherence tomography study. <i>International Journal of Cardiology</i> , 2020, 312, 27-32.	0.8	0
48	The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial. <i>Clinical Research in Cardiology</i> , 2020, 109, 1125-1139.	1.5	14
49	Impact of ticagrelor monotherapy on two-year clinical outcomes in patients with long stenting: a post hoc analysis of the GLOBAL LEADERS trial. <i>EuroIntervention</i> , 2020, 16, 634-644.	1.4	6
50	Ticagrelor monotherapy beyond one month after PCI in ACS or stable CAD in elderly patients: a pre-specified analysis of the GLOBAL LEADERS trial. <i>EuroIntervention</i> , 2020, 15, e1605-e1614.	1.4	20
51	Aspirin-free antiplatelet regimens after PCI: when is it best to stop aspirin and who could ultimately benefit?. <i>EuroIntervention</i> , 2020, 15, 1125-1129.	1.4	8
52	Combining anatomy and physiology: New angiography-based and computed tomography coronary angiography-derived fractional flow reserve indices. <i>Cardiology Journal</i> , 2020, 27, 225-229.	0.5	5
53	Alternative methods for functional assessment of intermediate coronary lesions. <i>Cardiology Journal</i> , 2020, 27, 825-835.	0.5	2
54	Chronic Total Occlusion 5 Years After Bioresorbable Vascular Scaffold Implantation: A Serial Optical Coherence Tomography Assessment. <i>Journal of Invasive Cardiology</i> , 2020, 32, E141.	0.4	0

#	ARTICLE	IF	CITATIONS
55	Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial. <i>European Heart Journal</i> , 2019, 40, 2595-2604.	1.0	93
56	Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2015-2027.	1.2	23
57	Ascertainment of Silent Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention (from the GLOBAL LEADERS Trial). <i>American Journal of Cardiology</i> , 2019, 124, 1833-1840.	0.7	5
58	Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes. <i>JAMA Cardiology</i> , 2019, 4, 1092.	3.0	97
59	Clinical Implication of Quantitative Flow Ratio After Percutaneous Coronary Intervention for 3-Vessel Disease. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 2064-2075.	1.1	71
60	Mechanical properties and performances of contemporary drug-eluting stent: focus on the metallic backbone. <i>Expert Review of Medical Devices</i> , 2019, 16, 211-228.	1.4	27
61	Clinical practice and ethics vs. statistics: considerations on Heart Team's decision testing study. <i>European Heart Journal</i> , 2019, 40, 1816-1817.	1.0	1
62	Predictive ability of ACEF and ACEF II score in patients undergoing percutaneous coronary intervention in the GLOBAL LEADERS study. <i>International Journal of Cardiology</i> , 2019, 286, 43-50.	0.8	19
63	Guided de-escalation of DAPT in acute coronary syndrome patients undergoing percutaneous coronary intervention with BVS implantation: a post-hoc analysis from the randomized TROPICAL-ACS trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 427-435.	1.0	3
64	A serial 3- and 9-year optical coherence tomography assessment of vascular healing response to sirolimus- and paclitaxel-eluting stents. <i>International Journal of Cardiovascular Imaging</i> , 2019, 35, 9-21.	0.7	2
65	Prasugrel monotherapy after PCI with the SYNERGY stent in patients with chronic stable angina or stabilised acute coronary syndromes: rationale and design of the ASET pilot study. <i>EuroIntervention</i> , 2019, 15, e547-e550.	1.4	16
66	Validation of the updated logistic clinical SYNTAX score for all-cause mortality in the GLOBAL LEADERS trial. <i>EuroIntervention</i> , 2019, 15, e539-e546.	1.4	16
67	Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: insights from the randomised GLOBAL LEADERS trial. <i>EuroIntervention</i> , 2019, 15, e1090-e1098.	1.4	16
68	Platelet to red cell distribution width ratio for predicting clopidogrel efficacy in patients undergoing percutaneous coronary interventions: insights from ONSIDE-TEST study. <i>Polish Archives of Internal Medicine</i> , 2019, 129, 117-122.	0.3	5
69	Quantitative flow ratio derived from diagnostic coronary angiography in assessment of patients with intermediate coronary stenosis: a wire-free fractional flow reserve study. <i>Clinical Research in Cardiology</i> , 2018, 107, 858-867.	1.5	21
70	Pretransplant QT Interval: The Relationship with Severity and Etiology of Liver Disease and Prognostic Value After Liver Transplantation. <i>Annals of Transplantation</i> , 2018, 23, 622-630.	0.5	14
71	First serial optical coherence tomography assessment at baseline, 12 and 24 months in STEMI patients treated with the second-generation Absorb bioresorbable vascular scaffold. <i>EuroIntervention</i> , 2018, 13, 2201-2209.	1.4	6
72	Negative predictors of treatment success in outpatient therapy of arterial hypertension in Poland. Results of the CONTROL NT observational registry. <i>Kardiologia Polska</i> , 2018, 76, 353-361.	0.3	8

#	ARTICLE	IF	CITATIONS
73	In-Scaffold Neovascularization 24 Months After Bioresorbable Vascular Scaffold Implantation in a Patient With ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, e123-e125.	1.1	4
74	Cell-derived microvesicles in cardiovascular diseases and antiplatelet therapy monitoring – A lesson for future trials? Current evidence, recent progresses and perspectives of clinical application. <i>International Journal of Cardiology</i> , 2017, 226, 93-102.	0.8	20
75	Implementation of mild therapeutic hypothermia for post-resuscitation care of sudden cardiac arrest survivors in cardiology units in Poland. <i>Advances in Clinical and Experimental Medicine</i> , 2017, 26, 1207-1212.	0.6	4
76	Galectin-3 in Patients with Acute Heart Failure: Preliminary Report on First Polish Experience. <i>Advances in Clinical and Experimental Medicine</i> , 2016, 25, 617-623.	0.6	16
77	A 12-month angiographic and optical coherence tomography follow-up after bioresorbable vascular scaffold implantation in patients with ST-segment elevation myocardial infarction. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 86, E180-9.	0.7	17
78	Circulating microribonucleic acids miR-1, miR-21 and miR-208a in patients with symptomatic heart failure: Preliminary results. <i>Archives of Cardiovascular Diseases</i> , 2015, 108, 634-642.	0.7	50
79	Subacute thrombosis after primary percutaneous coronary intervention with bioresorbable vascular scaffold implantation. <i>Kardiologia Polska</i> , 2015, 73, 300-300.	0.3	0